IB Delta T1 Maps
Comparison of standardized (calibrated) pre- (T1) and post-contrast (T1+C) anatomic images.
![DeltaT1-1024x439](https://blackfordanalysis.com/hs-fs/hubfs/DeltaT1-1024x439.png?width=824&height=353&name=DeltaT1-1024x439.png)
Overview
Reader misinterpretation and disagreement can contribute to radiologist burnout and diagnostic errors. Standard T1+C imaging can be variable and confounded by other bright enhancing signals, such as post-surgical blood product and may miss subtle enhancing regions which may not appear as an area of concern until weeks or months later in the treatment plan.
Delta T1 Maps aims to resolve this by detecting subtle regions of enhancing while subtracting out blood product and other artifacts that may appear bright on pre-contrast images.
![imagingBiometrics imagingBiometrics](https://blackfordanalysis.com/hs-fs/hubfs/imagingBiometrics.png?width=300&height=68&name=imagingBiometrics.png)
![Neuro-icon-150x150](https://blackfordanalysis.com/hs-fs/hubfs/Blackford%20Website/Partners/Neuro-icon-150x150.png?width=150&height=150&name=Neuro-icon-150x150.png)
![MRI-icon-1-300x300](https://blackfordanalysis.com/hs-fs/hubfs/Imported%20sitepage%20images/MRI-icon-1-300x300.png?width=300&height=300&name=MRI-icon-1-300x300.png)
![FDA CE UKCA icon](https://blackfordanalysis.com/hs-fs/hubfs/FDA%20%20CE%20%20UKCA%20icon.png?width=700&height=700&name=FDA%20%20CE%20%20UKCA%20icon.png)
Features
- Compares standardized (calibrated) pre- (T1) and post-contrast (T1+C) anatomic images.
- Aids in detecting subtle regions of contrast enhancement that may otherwise be missed on conventional T1+C images.
- Provides consistent determination of tumor regions of interest across time.
- Independent of scanner field strength, vendor, patient, or time point.
Benefits
- Aids in detection of tumor regions (free of blood products) which is becoming increasingly useful in longitudinal analysis of patients treated with antiangiogenic agents and other new treatment therapies.
- Enables visualization of post-surgical residual tumor and have been shown to be predictive of treatment response¹.
- Quantifies absolute residual tumor volume (RTV) which can help stratify the extent of glioblastoma resection.
- May be used intra-operatively.
Image examples
If you’re interested in learning more about this solution, or the 100+ other applications we have available on Blackford platform book a call with our friendly team now!
![review image 1](https://6395217.fs1.hubspotusercontent-na1.net/hubfs/6395217/Blackford-Analysis-team.png)
Book a meeting
We’d welcome the opportunity to learn more about your AI needs and to explain how partnering with Blackford can drive efficiency and provide ongoing value.
Book a Meeting¹Schmainda KM, Prah MA, Zhang Z, Snyder BS, Rand SD, Jensen TR, et al. Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial. AJNR American journal of neuroradiology [Internet]. 2019 Jul 1 [cited 2023 May 2];40(7):1132–9.